Transaction overview
Raymond Debbane, who serves on the board of Lexicon Pharmaceuticals, purchased 2,000 shares of the company’s common stock on February 25, 2026, at $1.49 per share, according to a Form 4 filed with the Securities and Exchange Commission. The purchase totaled $2,980.
Post-transaction holdings
Following the acquisition, Debbane directly holds 1,906,186 shares of Lexicon common stock. The Form 4 discloses additional indirect holdings attributed to entities and affiliated partnerships: 1,538,462 shares held by Avicenna Life Sci Master Fund LP; 7,362,368 shares by Invus Public Equities, L.P.; 5,451,204 shares by Invus US Partners, LLC; and 35,402,689 shares held by Invus, L.P. and related parties.
Market context and valuation signals
Lexicon’s shares have risen 124% in the past year, based on InvestingPro data referenced in the filing. At the time of the filing the stock was trading at $1.50, which InvestingPro lists as slightly above its Fair Value estimate of $1.38 and categorizes the name on its Most Overvalued list. The company reported a market capitalization of $634 million.
Recent capital markets activity
Lexicon has recently completed a combined underwritten public offering and concurrent private placement that together amounted to $100 million. As part of that financing, the company sold 32 million shares of common stock in the public offering at $1.30 per share. Concurrently, the private placement included 22.4 million common shares and 367,145 shares of Series B Convertible Preferred Stock priced at $65 per share. That transaction closed on February 2, 2026.
Separately, the company announced pricing for its public offering that was expected to generate $41.6 million in gross proceeds, with a closing anticipated around February 2, 2026. Lexicon also granted the underwriters a 30-day option to buy up to an additional 4.8 million shares at the same $1.30 price.
Clinical development update
The U.S. Food and Drug Administration has cleared Lexicon’s pilavapadin to proceed into Phase 3 development for the treatment of diabetic peripheral neuropathic pain. The planned Phase 3 program will consist of two placebo-controlled, 12-week studies designed to evaluate the efficacy of a 10 mg once-daily dose.
What the filing shows
The Form 4 documents a modest personal purchase by a director amid a period of equity issuance and an important clinical milestone for the company. The filing records precise ownership figures and reiterates recent financing and regulatory developments disclosed by the company.
Note: The article is based on the information contained in public filings and company announcements cited in the filing.